Ivermectin for Parkinson’s and Dementia: Analyzing the Neuroprotective Molecular Evidence and Clinical Case Reports (2026)
Scientific Review & Regulatory Audit by the Clinical Editorial Team The therapeutic paradigm for progressive neurodegenerative disorders like Parkinson’s disease (PD) and various forms of dementia faces a critical bottleneck. Standard pharmacology, primarily anchored by levodopa (L-DOPA) for Parkinson’s and acetylcholinesterase inhibitors for dementia, remains strictly symptomatic. These options frequently suffer from diminishing efficacy and significant side-effect profiles like L-DOPA-induced dyskinesia over long-term use. Consequently, the pharmaceutical community has focused heavily on drug repurposing—identifying established, safety-vetted compounds capable of crossing pathways to modify disease progression. An unexpected frontline candidate emerging in this space is ivermectin. Traditionally classified as a broad-spectrum antiparasitic agent, a surge of preclinical studies between 2020 and 2024 has unveiled its complex, multi-targeted pharmacodynamics within the mam...